← Leaderboards
John G Nutt
Oregon Health And Science University
$2,852,847
Attributed
$2,864,347
Total exposure
10
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $356.7K · FY2005–10$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$2,864,347 · 10
By mechanism
R01$1,756,241 · 1
M01$1,085,106 · 8
R13$23,000 · 1
Top collaborators
- Fay Bahling Horak2 shared
Most similar at Oregon Health And Science University
Same institution · by research overlap
- Fay Bahling Horak$25,060,241
- Carlos Antonio Paladini$7,640,283
- Steven William Johnson$6,453,458
- Kim J Burchiel$187,142
- Richard Camicioli$172,411
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchParkinson'S DiseaseHuman Therapy EvaluationLevodopaBrain Disorder ChemotherapyClinical TrialsApomorphineDrug Screening /EvaluationPharmacokineticsCircadian RhythmsDrug InteractionsDihydroxyphenylalanineDopamineNeuropharmacologyMethylphenidatePatient Oriented ResearchDopamine TransporterElectrodesBrain Electronic StimulatorLenticular NucleusParkinson DiseaseDrug MetabolismNervous System Disorder Therapy
Grant awards (29)
Freezing of Gait: From clinical phenomena to basic mechanisms of gait and balance$15,000
R13 · FY2010 · NS · contact PI
Freezing of Gait: From clinical phenomena to basic mechanisms of gait and balance$8,000
R13 · FY2009 · NS · contact PI
Levodopa Pharmacokinetics and Pharmacodynamics$282,987
R01 · FY2008 · NS · contact PI
Levodopa Pharmacokinetics and Pharmacodynamics$273,672
R01 · FY2007 · NS · contact PI
Levodopa Pharmacokinetics and Pharmacodynamics$281,217
R01 · FY2006 · NS · contact PI
Levodopa Pharmacokinetics and Pharmacodynamics$285,785
R01 · FY2005 · NS
METHYLPHENIDATE IN PARKINSON'S DISEASE$70,887
M01 · FY2005 · RR
Paroxetine in Parkinson's disease$49,499
M01 · FY2004 · RR
Methylphenidate in PD$45,833
M01 · FY2004 · RR
Levodopa Pharmacokinetics and Pharmacodynamics$36,666
M01 · FY2004 · RR
DBS , Deep Brain Stimulation and Levodopa$20,166
M01 · FY2004 · RR
Levodopa Pharmacokinetca and Pharmacodynamics$207,120
R01 · FY2003 · NS
Levodopa Pharmacokinetca and Pharmacodynamics$207,120
R01 · FY2002 · NS
Levodopa Pharmacokinetca and Pharmacodynamics$218,340
R01 · FY2001 · NS
DIURNAL PATTERNS OF MOTOR PERFORMANCE IN PARKINSON'S DISEASE$172,411
M01 · FY2001 · RR
LEVODOPA PHARMACOKINETICS AND PHARMACODYNAMICS$172,411
M01 · FY2001 · RR
CAN APOMORPHINE PRODUCE A LONG DURATION RESPONSE$172,411
M01 · FY2001 · RR
TAPPING SPEED IN NORMAL SUBJECTS--AGE AND CIRCADIAN INFLUENCES$172,411
M01 · FY2001 · RR
Deep brain stimulation &levodopa--Comparision, contrasts &interactions$172,411
M01 · FY2001 · RR
Deep brain stimulation &levodopa--Comparision, contrasts &interactions$0
M01 · FY2001 · RR
LEVODOPA PHARMACOKINETICS AND PHARMACODYNAMICS$0
M01 · FY2001 · RR
TAPPING SPEED IN NORMAL SUBJECTS--AGE AND CIRCADIAN INFLUENCES$0
M01 · FY2001 · RR
DIURNAL PATTERNS OF MOTOR PERFORMANCE IN PARKINSON'S DISEASE$0
M01 · FY2001 · RR
CAN APOMORPHINE PRODUCE A LONG DURATION RESPONSE$0
M01 · FY2001 · RR
LEVODOPA PHARMACOKINETICS AND PHARMACODYNAMICS$0
M01 · FY2000 · RR
Deep brain stimulation &levodopa--Comparision, contrasts &interactions$0
M01 · FY2000 · RR
CAN APOMORPHINE PRODUCE A LONG DURATION RESPONSE$0
M01 · FY2000 · RR
DIURNAL PATTERNS OF MOTOR PERFORMANCE IN PARKINSON'S DISEASE$0
M01 · FY2000 · RR
TAPPING SPEED IN NORMAL SUBJECTS--AGE AND CIRCADIAN INFLUENCES$0
M01 · FY2000 · RR